MRTX News and Press, Mirati Therapeutics Inc. From 10/27/20

Investors looking for biotech stocks to buy will notice lots of buzz around Amgen (NASDAQ: AMGN) and Mirati Therapeutics (NASDAQ: MRTX) lately. Both companies are developing similar new cancer treatments that could go on to generate billions in annual sales, and there are pl...

Mirati Therapeutics (MRTX) announces public offering of $700M of its common stock and a selling stockholder intends to offer 375k shares in the offering.Price and number of shares are yet to be determined. For further details see: Mirati Therapeutics launches equity offering of $70...

Shares of Mirati Therapeutics (NASDAQ: MRTX) were jumping 12.6% as of 11:17 a.m. EDT on Monday. The nice gain came after the company announced positive preliminary data on Sunday from phase 1/2 clinical studies of experimental drug adagrasib in treating advanced non-small cell lung ...

Gainers: Lianluo Smart (LLIT) +30%, Galera Therapeutics (GRTX) +18%, Selecta Biosciences (SELB) +16%, Mirati Therapeutics (MRTX) +14%, GeoVax Labs (GOVX) +14%.Losers: BioSig Technologies (BSGM) -40%, Aileron Therapeutics (ALRN) ...

Mirati Therapeutics (MRTX) reports preliminary results from its mutant KRAS selective inhibitor programs. The results included updated clinical data of adagrasib (MRTX849), a KRAS G12C inhibitor, presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics and initial ...

Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data - 45% confirmed ORR and 96% DCR across Phase 1/1b and Phase 2 monotherapy cohorts in patients ...

Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA) - Updated adagrasib (MRTX849) clinical data in non-small cell lung cancer (NSCLC) patients will be featured in a plenary session at ENA...

Mirati achieves positive results in phase 2 open-label study using sitravatinib to treat patients with metastatic or advanced urothelial carcinoma who have the KRAS mutation. Sitravatinib is a multi-kinase drug that targets RTK pathway which includes TAM family, VEGFR2 and KIT; This d...

Mirati Therapeutics (NASDAQ: MRTX ) has announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO) in patients with advanced or metastatic urothelial carcinoma. Data were presented at the European Society for Medical Oncolog...

SAN DIEGO , Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO ® ) in patients with ...